Details of the Drug

General Information of Drug (ID: DM42KZW)

Drug Name
DS-1093
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Phase 1 [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 130.15
Logarithm of the Partition Coefficient (xlogp) -3.5
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C5H10N2O2
IUPAC Name
piperazine-2-carboxylic acid
Canonical SMILES
C1CNC(CN1)C(=O)O
InChI
InChI=1S/C5H10N2O2/c8-5(9)4-3-6-1-2-7-4/h4,6-7H,1-3H2,(H,8,9)
InChIKey
JSSXHAMIXJGYCS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2723758
CAS Number
2762-32-5
TTD ID
D0E6VR

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF-prolyl hydroxylase (HPH) TTJQFBG NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anemia
ICD Disease Classification 3A00-3A9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HIF-prolyl hydroxylase (HPH) DTT NO-GeName 7.70E-01 4.40E-03 0.02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02299661) Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
2 Company report (Daiichisankyo)